Prasugrel (Maleic acid)

Modify Date: 2024-01-09 09:50:46

Prasugrel (Maleic acid) Structure
Prasugrel (Maleic acid) structure
Common Name Prasugrel (Maleic acid)
CAS Number 389574-20-3 Molecular Weight 489.51300
Density N/A Boiling Point N/A
Molecular Formula C24H24FNO7S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Prasugrel (Maleic acid)


Prasugrel Maleic acid is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel Maleic acid is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel Maleic acid reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel Maleic acid AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia; Nausea; Epistaxis

 Names

Name prasugrel maleate salt
Synonym More Synonyms

 Prasugrel (Maleic acid) Biological Activity

Description Prasugrel Maleic acid is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel Maleic acid is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel Maleic acid reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel Maleic acid AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia; Nausea; Epistaxis
Related Catalog
References

[1]. Baker WL, et al. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Am J Cardiovasc Drugs. 2009;9(4):213-29.

[2]. Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51. Epub 2007 Apr 19.

 Chemical & Physical Properties

Molecular Formula C24H24FNO7S
Molecular Weight 489.51300
Exact Mass 489.12600
PSA 149.45000
LogP 3.54070
Storage condition 2-8℃

 Synonyms

2-acetyloxy-5-(α-cycloproylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine maleate
2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine maleate
2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine maleate
5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate maleate
prasugrel maleate
Prasugrel (Maleic acid)